BridgeBio Pharma, Inc.

The stock remains in a strong multi-month uptrend, trading well above its 200-day moving average of 69.65 and not far from its 52-week high of 93.42. That keeps the primary regime constructive, though the move has already retraced a large part of the prior year’s range from 42.09.

Street sentiment stays constructive: consensus is Buy with a 104.70 average target, implying room above the current setup. Recent action is mixed but still favorable, with H.C. Wainwright raising its target to 120 and Citigroup reiterating Neutral, while several firms have held positive ratings.

Expect a loss-making quarter with the next print set for 2026-08-04, after a recent run of misses: BBIO has beaten EPS in only 2 of the last 7 quarters. Analysts still look for a sharp improvement, with next-year EPS estimated at 0.5687 versus TTM EPS of -3.68.

Recent insider activity leans negative, driven by net selling rather than fresh buying. The July 9 cluster includes director Andrea Ellis and director Jennifer Cook, but the M-Exempt entries are automatic and should be treated as noise; the discretionary S-Sale filings are the signal, and they point to distribution.

Profitability remains weak despite strong top-line momentum. Gross margin is 95.1%, but operating margin is -54.47% and net margin is -124.42%, while revenue growth is 66.8% year over year. Cash burn is still heavy, with operating cash flow of -445.9 million and free cash flow of -444.8 million.

BBIO screens like a high-beta biotech with commercial and pipeline optionality, not a mature cash compounder. The valuation still looks rich versus the sector on a -22.1 P/E, but the market is paying for growth and a path toward earnings inflection.